Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.
Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...
St. Paul's Episcopal quarterback Kenny Johnson makes a throw on the run as Murphy High linebacker Kyan Parker-Crawford fights ...
Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...
Tyra Biosciences receives an upgrade from BofA, raising the price target to $31. The upgrade follows promising preclinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback